View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Merck KGaA: Update following affirmation of A3 rating, outlook remains...

Our credit view of this issuer reflects its operational diversification and conservative financial policies, mitigated by a significant risk of acquisitions.

Ahmed Ben Salem
  • Ahmed Ben Salem

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/15/2024

Swiss-based Accelleron was formed from the spin-off of ABB’s highly profitable turbocharger division in 2022. We view the share as a promising investment on 1/ market leadership in an attractive niche, 2/ about ~40% ROCE, 3/ conversion of ~80% of EBITDA into cash, leading to fast deleveraging, and a solid base for shareholder remuneration (75% pay out), and 4/ strong long-term visibility linked to a ~75% service share, the bulk of which is recurring. Despite an already strong stock pe...

Oliver Metzger
  • Oliver Metzger

Merck KGaA : Turnaround for Process solutions – highly attractive entr...

>Life Sciences – the turnaround for Process solutions - While there is still some residual headwind related to destocking and the changing ordering pattern of customers, the 3.7% organic growth in Q3 was a clear positive surprise. The company highlighted that sales and order intake increased sequentially q-o-q. For the fourth quarter, additional sequential growth was indicated not only in absolute terms, but also as organic growth rate. We assume 5% organic growth for...

Oliver Metzger
  • Oliver Metzger

Merck KGaA : Q3 review – turnaround for Process solutions

>Q3 review – beat on EBITDA pre level, guidance confirmed - Merck’s Q3 revenues of € 5,266m (+1.8% y-o-y) were driven by organic growth of 3.8% and were 0%/-1% vs ODDO BHF/consensus. On the bottom line, the company reported EBITDA pre of € 1,618m (+11.9% y-o-y, margin 30.7%), 5% ahead of expectations. EPS pre reached € 2.30, in line with expectations. The 2024 guidance was confirmed with revenues in the range of € 20.7bn to € 22.1bn, trending towards the lower half of...

Oliver Metzger
  • Oliver Metzger

Merck KGaA : CMD feedback – Turn to the better and de-risking

>Focus on lower capital intensity over the next years - Following some years of elevated capex projects, CFO Helene von Roeder indicated lower capital expenditure in absolute terms that support an improving cash conversion backed also by an improving sales mix. As a result, free cash flow is expected to improve. Regarding the allocation of capital for potential acquisitions, a substantial amount is allocated towards the Life Sciences segment. For Healthcare, a de-risk...

Moody's Ratings assigns Baa2 rating to Merck's new hybrid notes

Moody's Ratings (Moody's) has today assigned a Baa2 junior subordinated rating to the proposed €800 million fixed to reset rate notes due 2054 (the hybrid) issued by Merck KGaA (Merck or the company). The outlook is stable. Merck intends to use the proceeds of the new hybrid issuance, for general ...

Oliver Metzger
  • Oliver Metzger

Merck KGaA : Incorporating higher estimates for Healthcare and Electro...

>Second quarter with strong quarter for Healthcare and Electronics - Merck had already reported, on 26 July, preliminary Q2 results ahead of expectations with revenues of € 5,352m (+0.9% y-o-y). On the bottom line, the company reported EBITDA pre of € 1,509m (-2.9% y-o-y, margin 28.2%). EPS pre reached € 2.20. The company now expects revenues in the range of € 20.7bn to € 22.1bn (previously € 20.6bn to € 22.1bn), which compares to our new forecast of € 21.4bn. On EBIT...

Oliver Metzger
  • Oliver Metzger

Merck KGaA : Q2 review – Strong set of numbers, Process solutions move...

>Top and bottom-line results on group level already reported - Merck had already reported, on 26 July, preliminary Q2 results ahead of expectations with revenues of € 5,352m (+0.9% y-o-y). On the bottom line, the company reported EBITDA pre of € 1,509m (-2.9% y-o-y, margin 28.2%). EPS pre reached € 2.20. The company now expects revenues in the range of € 20.7bn to € 22.1bn (previously € 20.6bn to € 22.1bn) On EBITDA pre, Merck now sees a range of € 5.8bn to € 6.4bn (p...

Bruno Cavalier ... (+3)
  • Bruno Cavalier
  • Oliver Metzger
  • Wim Gille

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 07/29/2024

Questions are mounting for the equity markets on multiple fronts: economic (turbulence or slowdown), monetary (how quickly will central banks cut rates) and geopolitical (France, US, Russia/Ukraine, China). For the rest of the summer, we are maintaining our positive bias on US vs European equities. On European equities, we are returning to a neutral stance between cyclicals and defensives, between value and growth styles, between large caps and small caps, and recommend increasing pos...

Bruno Cavalier ... (+3)
  • Bruno Cavalier
  • Oliver Metzger
  • Wim Gille

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 29/07/2024

Les questions s’accumulent pour les marchés actions : sur les plans économique (trou d’air ou ralentissement ?), monétaire (à quel rythme les banques centrales vont-elles baisser les taux) et (géo)politique (France, Etats-Unis, Russie/Ukraine, Chine). Pour le reste de cet été, nous conservons notre biais positif sur les actions américaines vs européennes. Sur les actions européennes, nous revenons à la neutralité entre cycliques et défensives, entre les styles Value et Growth, entre L...

Oliver Metzger
  • Oliver Metzger

Merck KGaA : Q2 beat driven by Healthcare and Electronics

>Preliminary results driven by Healthcare and Electronics - Merck reported preliminary Q2 results with revenues of € 5,352m (+0.9% y-o-y), which were 1% ahead of our forecast and 2% ahead of consensus. While the company did not provide results on a segmental base, the better than expected performance was driven by the Healthcare and the Electronics division. The development of the Life Science division was described as within expectations. On the bottom line, the comp...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch